Abstract:Motivation: Drug-target interactions (DTIs) hold a pivotal role in drug repurposing and elucidation of drug mechanisms of action. While single-targeted drugs have demonstrated clinical success, they often exhibit limited efficacy against complex diseases, such as cancers, whose development and treatment is dependent on several biological processes. Therefore, a comprehensive understanding of primary, secondary and even inactive targets becomes essential in the quest for effective and safe treatments for cancer and other indications. The human proteome offers over a thousand druggable targets, yet most FDA-approved drugs bind to only a small fraction of these targets. Results: This study introduces an attention-based method (called as MMAtt-DTA) to predict drug-target bioactivities across human proteins within seven superfamilies. We meticulously examined nine different descriptor sets to identify optimal signature descriptors for predicting novel DTIs. Our testing results demonstrated Spearman correlations exceeding 0.72 (P < 0.001) for six out of seven superfamilies. The proposed method outperformed fourteen state-of-the-art machine learning, deep learning and graph-based methods and maintained relatively high performance for most target superfamilies when tested with independent bioactivity data sources. We computationally validated 185 676 drug-target pairs from ChEMBL-V33 that were not available during model training, achieving a reasonable performance with Spearman correlation >0.57 (P < 0.001) for most superfamilies. This underscores the robustness of the proposed method for predicting novel DTIs. Finally, we applied our method to predict missing bioactivities among 3492 approved molecules in ChEMBL-V33, offering a valuable tool for advancing drug mechanism discovery and repurposing existing drugs for new indications. Availability and implementation: https://github.com/AronSchulman/MMAtt-DTA.

Systematic Investigation of Dual-Target-Directed Ligands

Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands

A Unified Conditional Diffusion Framework for Dual Protein Targets Based Bioactive Molecule Generation

Recent advances in multitarget-directed ligands via in silico drug discovery

Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy.

Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors

Recent Advances In The Rational Drug Design Based On Multi-Target Ligands

Multiple Target Drug Design Using LigBuilder 3

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Multitarget-Directed Ligands Hitting Serotonin Receptors: A Medicinal Chemistry Survey

Ligand-Based Approach for Multi-Target Drug Discovery: PTML Modeling of Triple-Target Inhibitors

Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.

Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery

A Novel Strategy for Designing the Magic Shotguns for Distantly Related Target Pairs

Automated design of multi-target ligands by generative deep learning

Computational Multitarget Drug Design.

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins

Molecular hybridization: a powerful tool for multitarget drug discovery

MTDL-GAN: De novo Design of Multi-Target Directed Ligands for Alzheimer’s Disease from Unpaired Sets of Target-Focused Chemical Library

Attention-based approach to predict drug-target interactions across seven target superfamilies

Computer Aided Multi-target Drug Design, Multi-target Virtual Screening